Hide metadata

dc.date.accessioned2017-01-11T10:08:42Z
dc.date.available2017-01-11T10:08:42Z
dc.date.created2016-11-22T13:38:36Z
dc.date.issued2016
dc.identifier.citationLenartova, Andrea Johannessen, Tom Børge Tjønnfjord, Geir Erland . National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953–2012: a systematic analysis of population-based data. Cancer Medicine. 2016
dc.identifier.urihttp://hdl.handle.net/10852/53509
dc.description.abstractChronic lymphocytic leukemia is a disease of the elderly, and despite major advances in treatment, remains incurable. The Cancer Registry of Norway has registered data on patients with chronic lymphocytic leukemia since 1953. We aimed to analyze trends in incidence and survival of chronic lymphocytic leukemia in Norway. We identified 7664 patients reported with chronic lymphocytic leukemia to the registry between 1953 and 2012. We gathered information on sex, age at diagnosis, date of death and basis for diagnosis. The age-standardized incidence increased from 0.6/100.000 person-years in 1953 to 3.1/100,000 person-years in 2012. We found a significant decrease in median age between 1993–2002 and 2003–2012 (75 vs. 72 years, 95%CI: 2.52–3.98, P < 0.001). Men were diagnosed at a significantly younger age than women. Immunophenotyping has become the most important diagnostic method after 2002. Median observed survival increased from 3 years in 1952–1963 to 8.5 years in 2003–2012. Five- and 10-year age-standardized net survival increased throughout the whole period across age groups and reached 79% and 57%, respectively. Median observed survival was significantly shorter in men than in women in 1993–2002 (4.9 vs. 6.1 years, P < 0.001). The gap between survival rates for men and women was diminishing in 2003–2012 in patients younger than 60 years while it remained considerable in older patients. Despite an aging Norwegian population, chronic lymphocytic leukemia (CLL) patients become younger at diagnosis. A fourfold increase in incidence, a prolonged survival, and major changes in diagnostic methods in Norway were observed.en_US
dc.languageEN
dc.language.isoenen_US
dc.relation.ispartofLenartova, Andrea (2020) Chronic lymphocytic leukemia in Norway 1953-2012. Doctoral thesis http://hdl.handle.net/10852/81117
dc.relation.urihttp://hdl.handle.net/10852/81117
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleNational trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953–2012: a systematic analysis of population-based dataen_US
dc.typeJournal articleen_US
dc.creator.authorLenartova, Andrea
dc.creator.authorJohannessen, Tom Børge
dc.creator.authorTjønnfjord, Geir Erland
cristin.unitcode185,53,49,0
cristin.unitnameKreftklinikken
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1402923
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Cancer Medicine&rft.volume=&rft.spage=&rft.date=2016
dc.identifier.jtitleCancer Medicine
dc.identifier.volume5
dc.identifier.issue12
dc.identifier.startpage3588
dc.identifier.endpage3595
dc.identifier.doihttp://dx.doi.org/10.1002/cam4.849
dc.identifier.urnURN:NBN:no-56701
dc.type.documentTidsskriftartikkelen_US
dc.type.peerreviewedPeer reviewed
dc.source.issn2045-7634
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/53509/1/Lenartova_et_al-2016-Cancer_Medicine.pdf
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International